Canine status epilepticus: A translational platform for human therapeutic trials

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalEpilepsia
Volume52
Issue numberSUPPL. 8
DOIs
StatePublished - Oct 1 2011

Fingerprint

Status Epilepticus
Canidae
etiracetam
Epilepsy
Therapeutics
Animal Models
Placebos
Pharmaceutical Preparations

Keywords

  • Canine epilepsy
  • Status epilepticus
  • Translational platform

Cite this

Canine status epilepticus : A translational platform for human therapeutic trials. / Leppik, Ilo E; Patterson, Ned; Coles, Lisa D; Craft, Elise M.; Cloyd, James C.

In: Epilepsia, Vol. 52, No. SUPPL. 8, 01.10.2011, p. 31-34.

Research output: Contribution to journalArticle

@article{a530d0fb925a4388a06cf4c30b3fdf35,
title = "Canine status epilepticus: A translational platform for human therapeutic trials",
abstract = "Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56{\%} response rate compared to 10{\%} for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.",
keywords = "Canine epilepsy, Status epilepticus, Translational platform",
author = "Leppik, {Ilo E} and Ned Patterson and Coles, {Lisa D} and Craft, {Elise M.} and Cloyd, {James C}",
year = "2011",
month = "10",
day = "1",
doi = "10.1111/j.1528-1167.2011.03231.x",
language = "English (US)",
volume = "52",
pages = "31--34",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL. 8",

}

TY - JOUR

T1 - Canine status epilepticus

T2 - A translational platform for human therapeutic trials

AU - Leppik, Ilo E

AU - Patterson, Ned

AU - Coles, Lisa D

AU - Craft, Elise M.

AU - Cloyd, James C

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

AB - Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

KW - Canine epilepsy

KW - Status epilepticus

KW - Translational platform

UR - http://www.scopus.com/inward/record.url?scp=80053590410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053590410&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2011.03231.x

DO - 10.1111/j.1528-1167.2011.03231.x

M3 - Article

C2 - 21967357

AN - SCOPUS:80053590410

VL - 52

SP - 31

EP - 34

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 8

ER -